Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.39 |
| ▸ | CA2 | P00918 | 3/20 | 0.35 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.35 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.35 |
| ▸ | LTA4H | P09960 | 1/20 | 0.32 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.32 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.32 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.31 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.31 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.31 |
| ▸ | TLR8 | Q9NR97 | 1/20 | 0.30 |
| ▸ | GPR17 | Q13304 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29529062 | 0.87 | KDM4E (0.36) | KDM4EPOLBALDH1A1CA2CYP4F2 | |
| SCHEMBL6582640 | 0.87 | KDM4E (0.36) | KDM4EPOLBALDH1A1CA2CYP4F2 | |
| SCHEMBL533943 | 0.87 | ALDH1A1 (0.48) | KDM4EPOLBALDH1A1CA2CYP4F2 | |
| SCHEMBL6518274 | 0.86 | EED (0.36) | KDM4EPOLBALDH1A1CA2CYP4F2 | |
| SCHEMBL16555192 | 0.85 | TDP1 (0.40) | KDM4EALDH1A1CA2CYP4F2CYP4A11 | |
| SCHEMBL20700086 | 0.81 | KDM4E (0.33) | KDM4EPOLBALDH1A1 | |
| SCHEMBL20718422 | 0.78 | ADRA2A (0.31) | KDM4EPOLBCA2TAAR1TDP1 | |
| Hydrochloric Acid SCHEMBL20700235 | 0.77 | KDM4E (0.33) | KDM4EPOLBTAAR1TDP1 | |
| Hydrochloric Acid SCHEMBL29981568 | 0.77 | KDM4E (0.33) | KDM4EPOLBTAAR1TDP1 | |
| SCHEMBL18243554 | 0.76 | ALDH1A1 (0.33) | ALDH1A1TAAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11491133-B2 | Heteroaryl-isochroman compounds and uses thereof | SUNOVION PHARMACEUTICALS INC. (US) | 2022-11-08 | — | — | US | disclosed |
| EP-3661929-B1 | ISOCHROMAN COMPOUNDS AND USES THEREOF | SUNOVION PHARMACEUTICALS INC (US) | 2021-07-14 | — | — | EP | disclosed |
| EP-3661929-B1 | ISOCHROMAN COMPOUNDS AND USES THEREOF | SUNOVION PHARMACEUTICALS INC (US) | 2021-07-14 | — | — | EP | disclosed |
| US-20210093606-A1 | COMPOUNDS AND USES THEREOF | SUNOVION PHARMACEUTICALS INC. (US) | 2021-04-01 | — | — | US | disclosed |
| US-10780074-B2 | Compounds and uses thereof | SUNOVION PHARMACEUTICALS INC. (US) | 2020-09-22 | — | — | US | disclosed |
| EP-3661929-A1 | ISOCHROMAN COMPOUNDS AND USES THEREOF | Sunovion Pharmaceuticals Inc. (US) | 2020-06-10 | — | — | EP | disclosed |
| WO-2019028165-A1 | ISOCHROMAN COMPOUNDS AND USES THEREOF | SUNOVION PHARMACEUTICALS INC. (US) | 2019-02-07 | — | — | WO | disclosed |
| WO-2019028165-A1 | ISOCHROMAN COMPOUNDS AND USES THEREOF | SUNOVION PHARMACEUTICALS INC. (US) | 2019-02-07 | — | — | WO | disclosed |
| US-20190038594-A1 | COMPOUNDS AND USES THEREOF | PGI DRUG DISCOVERY LLC | 2019-02-07 | — | — | US | disclosed |
| US-7928238-B2 | 1,2,3,4-tetrahydro-quinoline derivatives as CETP inhibitors | JANSSEN PHARMACEUTICA NV (BE) | 2011-04-19 | — | — | US | disclosed |
| US-7928238-B2 | 1,2,3,4-tetrahydro-quinoline derivatives as CETP inhibitors | JANSSEN PHARMACEUTICA NV (BE) | 2011-04-19 | — | — | US | disclosed |
| EP-2034998-A1 | 1,2,3,4-TETRAHYDRO-QUINOLINE DERIVATIVES AS CETP INHIBITORS | Janssen Pharmaceutica, N.V. (BE) | 2009-03-18 | — | — | EP | disclosed |
| WO-2008079427-A1 | 1,2,3,4-TETRAHYDRO-QUINOLINE DERIVATIVES AS CETP INHIBITORS | JANSSEN PHARMACEUTICA N.V. (BE) | 2008-07-03 | — | — | WO | disclosed |
| WO-2008079427-A1 | 1,2,3,4-TETRAHYDRO-QUINOLINE DERIVATIVES AS CETP INHIBITORS | JANSSEN PHARMACEUTICA N.V. (BE) | 2008-07-03 | — | — | WO | disclosed |
| US-20070265304-A1 | 1,2,3,4-TETRAHYDRO-QUINOLINE DERIVATIVES AS CETP INHIBITORS | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-11-15 | — | — | US | disclosed |
| US-20070265304-A1 | 1,2,3,4-TETRAHYDRO-QUINOLINE DERIVATIVES AS CETP INHIBITORS | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-11-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070265304-A1 | 1,2,3,4-TETRAHYDRO-QUINOLINE DERIVATIVES AS CETP INHIBITORS | CETP, NPC1, CES1 | KDM4E 1602/4885POLB 566/4885ALDH1A1 3257/4885 |
| US-20210093606-A1 | COMPOUNDS AND USES THEREOF | PYGB, NLN, MAOB | KDM4E 3953/4885POLB 2661/4885ALDH1A1 178/4885 |
| US-10780074-B2 | Compounds and uses thereof | PYGB, NLN, MAOB | KDM4E 3953/4885POLB 2661/4885ALDH1A1 178/4885 |
| US-20190038594-A1 | COMPOUNDS AND USES THEREOF | PYGB, NLN, MAOB | KDM4E 3953/4885POLB 2661/4885ALDH1A1 178/4885 |
| US-11491133-B2 | Heteroaryl-isochroman compounds and uses thereof | GRIN2C, INA, SDHA | KDM4E 2961/4885POLB 2793/4885ALDH1A1 704/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.